Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study.
CYP2B6
CYP2D6
methadone
pharmacokinetic
response to treatment
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
25
09
2018
revised:
07
03
2019
accepted:
17
03
2019
pubmed:
26
3
2019
medline:
3
7
2020
entrez:
26
3
2019
Statut:
ppublish
Résumé
Our study aimed to evaluate the impacts of the cytochrome P450 (CYP) 2B6-G516T and CYP2D6 genetic polymorphisms on pharmacokinetic and clinical parameters in patients receiving methadone maintenance treatment. Opioid PhArmacoLogy (OPAL) was a clinical survey of the sociodemographic characteristics, history and consequences of pathology associated with methadone maintenance treatment response and current addictive comorbidities. A subgroup of 72 methadone patients was genotyped. When comparing the three CYP2B6 genotype groups, the methadone (R)- and (S)-methadone enantiomer concentrations/doses (concentrations relative to doses) were different (P = .029, P = .0019). The CYP2D6 phenotypes did not seem to be relevant with regard to methadone levels. On multivariate analysis, neither the CYP2B6 genotype nor the CYP2D6 phenotype explained the (R)-methadone concentration/dose values (P = .92; P = .86); the (S)-methadone concentration/dose values (P = .052; P = .95 [although there was a difference between the TT group and GT and GG groups {P = .019}]); or opiate cessation (P = .12; P = .90). The genotyping of CYP2B6 G516T could be an interesting tool to explore methadone intervariability.
Identifiants
pubmed: 30907440
doi: 10.1111/bcp.13936
pmc: PMC6595468
doi:
Substances chimiques
CYP2B6 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP2B6
EC 1.14.14.1
Cytochrome P-450 CYP2D6
EC 1.14.14.1
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1538-1543Informations de copyright
© 2019 The British Pharmacological Society.
Références
Int J Neuropsychopharmacol. 2018 Oct 1;21(10):910-917
pubmed: 30060048
Pharmacogenomics J. 2011 Aug;11(4):258-66
pubmed: 20514076
PLoS Genet. 2016 Mar 24;12(3):e1005910
pubmed: 27010727
Pharmacogenomics J. 2018 Jan;18(1):173-179
pubmed: 27958381
Clin Pharmacol Ther. 2006 Dec;80(6):668-81
pubmed: 17178267
Clin Pharmacol Ther. 2004 Jul;76(1):55-63
pubmed: 15229464
Clin Pharmacokinet. 2002;41(14):1153-93
pubmed: 12405865
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1722-7
pubmed: 18687376
Epigenomics. 2016 Feb;8(2):181-95
pubmed: 26792095
Addict Behav. 1978;3(3-4):235-41
pubmed: 735910
Pharmacogenomics. 2014 May;15(7):1007-27
pubmed: 24956254
Pharmacogenet Genomics. 2013 Feb;23(2):84-93
pubmed: 23249875
J Clin Pharmacol. 2013 Mar;53(3):305-13
pubmed: 23361846
Arch Pediatr Adolesc Med. 1999 Jun;153(6):591-6
pubmed: 10357299
Ther Drug Monit. 2017 Oct;39(5):550-555
pubmed: 28723731
Am J Drug Alcohol Abuse. 2016 Sep;42(5):587-596
pubmed: 27284701
PLoS One. 2014 Jan 29;9(1):e86114
pubmed: 24489693
Nurse Educ. 1988 Sep-Oct;13(5):4-5
pubmed: 3211385
J Clin Psychopharmacol. 2001 Apr;21(2):229-34
pubmed: 11270921
Am J Drug Alcohol Abuse. 2018;44(4):431-440
pubmed: 29333880
Addict Biol. 2013 Jul;18(4):709-16
pubmed: 21790905
Pharmacogenomics. 2011 Nov;12(11):1525-33
pubmed: 21902500
J Food Drug Anal. 2013 Dec;21(4):S62-S68
pubmed: 25278738
Drug Metab Lett. 2016;10(3):213-218
pubmed: 27515451
Talanta. 2015 Mar;134:373-378
pubmed: 25618682
Clin Pharmacol Ther. 2005 Dec;78(6):593-604
pubmed: 16338275
Clin Pharmacol Ther. 2007 May;81(5):719-28
pubmed: 17329992
Clin Pharmacokinet. 2016 Dec;55(12):1521-1533
pubmed: 27286724
Psychol Med. 2005 Feb;35(2):245-56
pubmed: 15841682
Arch Intern Med. 2010 Mar 22;170(6):529-36
pubmed: 20308640
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Mol Diagn Ther. 2018 Feb;22(1):57-78
pubmed: 29168075
J Clin Psychopharmacol. 2011 Aug;31(4):463-9
pubmed: 21694616
Clin Pharmacol Ther. 2008 May;83(5):668-9; author reply 669-70
pubmed: 18043693
Compr Psychiatry. 2012 Jul;53(5):609-15
pubmed: 22036009
Crit Care. 2007;11(1):119
pubmed: 17338832
Drug Alcohol Depend. 2000 Dec 22;61(1):47-54
pubmed: 11064183
Biochem Pharmacol. 2018 Jul;153:196-204
pubmed: 29458047
Biomed Res Int. 2013;2013:741403
pubmed: 24455721
Presse Med. 2007 Apr;36(4 Pt 1):582-90
pubmed: 17276648
Am J Psychiatry. 1993 Jun;150(6):885-90
pubmed: 8494063
Br J Clin Pharmacol. 2019 Jul;85(7):1538-1543
pubmed: 30907440
Br J Clin Pharmacol. 2015 Jun;79(6):967-77
pubmed: 25556837
Br J Pharmacol. 2017 Dec;174 Suppl 1:S17-S129
pubmed: 29055040
Rev Med Suisse Romande. 2000 Feb;120(2):111-6
pubmed: 10748696
Compr Psychiatry. 2010 May-Jun;51(3):325-31
pubmed: 20399344
Int J Addict. 1994 Jan;29(2):135-60
pubmed: 8144272
Pharmacology. 2007;80(4):304-11
pubmed: 17690563
Eur J Clin Pharmacol. 2009 Nov;65(11):1113-20
pubmed: 19639308